Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 20

10:45 EST 25th February 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 476–500 of 6,200+

Probably Relevant

FDA clears Anika Therapeutics' HA-based bone filler

Anika Therapeutics secured 510(k) clearance from the FDA for its injectable HA-based bone void filler, which can be used to t -More- 


Last Chance to Save on Boston’s Life Science Disruptors

There’s just eight days left before Xconomy’s latest biotech event, “Boston’s Life Science Disruptors.” Don’t let the clock run out while you can still save some cash on a ticket. Next Thursday, September 28, we’re bringing together some of the key founders and investors behind three cancer drugmakers—Tesaro, Dragonfly Therapeutics, and IFM Therapeutics—that have each [&#...

Prime Therapeutics Study Finds A Diabetes Drugs Value Based Insurance Design Improves Adherence, Doesn't Lower Total Cost Of Care

ST. PAUL, Minn., Oct. 13, 2017 /PRNewswire/ --Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 20 million members nationally, found that implementing value based insurance designs (VBID) does not lead...


Opioid Arrest: Insys Therapeutics founder indicted

PHOENIX (AP) — U.S. prosecutors brought a fraud and racketeering case Thursday against the founder of an opioid medication maker, Insys Therapeutics (NASDAQ:INSY), that has faced increasing scrutiny from authorities across the country over allegations of pushing prescriptions of powerful painkillers amid a drug epidemic that is claiming thousands of lives each year.

Summit Therapeutics nets $18.9mm via FOPO of ADSs

Summit Therapeutics PLC (working on therapies for Duchenne muscular dystrophy and Clostridium difficile infection) netted $18...

Seattle in $614m move for Cascadian Therapeutics

Things don’t always go quite according to plan in the biotech world – something both Seattle Genetics and Cascadian Therapeutics know only too well. Seattle Genetics was thwarted in its attempted $2 billion licensing deal with Immunomedics, for its lead solid-tumour drug, by activist investors that weren’t prepared to accept the deal offered by the former company. read more

Vertex, CRISPR Therapeutics To Co-develop And Co-commercialize CTX001

CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) and Switzerland-based CRISPR Therapeutics AG (CRSP) said that the companies will co-develop and co-commercialize CTX001, an...

Summit Therapeutics plc: Grant of share options

Summit Therapeutics plc ('Summit' or the 'Company')GRANT OF SHARE OPTIONS TO DIRECTORS, PDMRS AND EMPLOYEES AND GRANT OF RESTRICTED STOCK UNITS TO NON-EXECUTIVE DIRECTORSOxford, UK, 25 October 201...

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel

(Reuters) - PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S...

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

Crescita Therapeutics acquires INTEGA Skin Sciences

Crescita Therapeutics has acquired INTEGA Skin Sciences, a Montreal-based dermatology company which develops, manufactures, sells and markets science-based quality skin care products.

Allergy Therapeutics kicks off dosing in grass immunotherapy trial

Allergy Therapeutics has begun dosing in a mid-stage trial designed to assess the dose-response and safety of its ultra-short course PQ Grass immunotherapy, which targets the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

Kite, Sangamo Therapeutics Collab to Develop Next-generation Engineered Cell Therapies for the Treatment of Cancer

NewsKite and Sangamo Therapeutics announced the companies have entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.

FDA pours cold water on PTC Therapeutics' Duchenne application

PTC Therapeutics Inc has not supplied persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, a preliminary review by scientists at the U.S. Food and Drug Administration concluded. The review, posted on the FDA's website on Tuesday, said data to establish the effectiveness of the drug, ataluren, "are not persuasive."

Fate Therapeutics Wins $4M Grant to Advance NK Cancer Immunotherapy

Fate Therapeutics said today it has won a $4 million California Institute for Regenerative Medicine grant toward advancing one of its off-the-shelf engineered natural killer (NK) cell cancer immunotherapies into a first-in-human clinical trial. FT516 is derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to uniformly express a novel CD16 Fc receptor that has been ...

Reviewing PAREXEL International

PAREXEL International and Crispr Therapeutics are both biotechnology & medical research - nec companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation. This is a breakdown of recent ratings and price targets for PAREXEL Internationa...

Protagonist Therapeutics nets $56.4mm via FOPO

GI-focused Protagonist Therapeutics Inc. (peptide therapies) netted $56.4mm via a follow-on public offering of 3.53mm common ...

Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent

Somerset, N.J. (PRWEB) October 02, 2017 Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today welcomed Symbiomix Therapeutics’ announcement that the U.S. Food and Drug Adminis...

United Therapeutics to Pay $210 Million to Resolve False Claims From Paying of Beneficiary’s Copays

Pharmaceutical company United Therapeutics (UT) has agreed to pay $210 million for False Claims Act and Anti-Kickback Statute claims against them. The government alleged that UT used a foundation as a conduit to pay the copays of Medicare patients taking UT drugs.

Global and Chinese Acute Respiratory Distress Syndrome Therapeutics Industry, 2017 Market Research Report [Report Updated: 24122017] Prices from USD $3000

The 'Global and Chinese Acute Respiratory Distress Syndrome Therapeutics Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Acute Respiratory Distress Syndrome Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Acute Respiratory Distress Syndrome Therapeutics manufac...

ViroMed Steps Up Global Ambitions With New Gene Therapy Pipeline

ViroMed, which is conducting late phase clinical trials of its gene therapy, VM202, in the US, hopes to emerge as...   

Takeda, HemoShear collaborate to develop drugs for liver diseases

Takeda has collaborated with HemoShear Therapeutics to discover and develop novel therapeutics for liver diseases such as nonalcoholic steatohepatitis (NASH).

AOBiome Therapeutics Promotes Todd Krueger to CEO

Todd Krueger has been named CEO of AOBiome Therapeutics. In addition to serving as CEO, Krueger will keep his current role as president of the Cambridge, MA, company, a position he has held since 2016. Krueger joined AOBiome in 2015 as chief business officer. AOBiome is developing microbiome treatments for local and systemic inflammatory conditions.

Private placement brings in $20mm for Trillium Therapeutics

Immuno-oncology firm Trillium Therapeutics Inc. grossed $20mm through a private sale of 1.95mm common shares at $8.50 (an 8% ...

Aclaris Therapeutics Receives FDA Approval for Eskata (hydrogen peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses

MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Eskata (hydrogen peroxide) topical...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks